Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

GlaxoSmithKline's Arzerra flunks lymphoma trial, dashing plans for expanded use

20.05.2014 / Fierce Pharma

GlaxoSmithKline has missed out on a big new market for its blood cancer drug Arzerra. Approved to treat chronic lymphocytic leukemia, Arzerra (ofatumumab) failed to pass the test in a B-cell lymphoma trial. And now, Glaxo officials say they're giving up on the indication.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: